Could a simple shot replace IV drips for tough bone infections?
NCT ID NCT01815541
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested whether giving the antibiotic teicoplanin as a shot under the skin is safe and well-tolerated in adults with bone and joint infections. Thirty patients who were already stable on IV teicoplanin received the subcutaneous version. The main goal was to check for injection-site reactions, not to measure how well the drug fought the infection.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- teicoplanin
- What this could lead to
- If successful, this could offer a more convenient way to give teicoplanin for bone infections, potentially reducing hospital stays.
- What could go wrong
- This is a small, early-phase study focused only on safety and local tolerance, not on whether the drug works. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
30 people
The number who actually took part.
- Start date
-
Mar 2013
- Finished
-
Jul 2015
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient over 18 years * Inpatient orthopedic surgery * Achieved a bone and joint infection documented gram + (staphylococci golden coagulase-negative staphylococci, enterococci, streptococci) * Bacteria resistant to lincosamides, quinolones and rifampicin * Bacteria susceptible to teicoplanin (MIC ≤ 4 mg / L) * Balanced patient teicoplanin administered intravenously (2 successive doses between 30 and 40 mg / mL) Exclusion Criteria: * Patient not affiliated to the social security * Pregnant and lactating women * Known hypersensitivity to teicoplanin (rash, ...) * Patients with a central catheter or an implantable chamber * Patient hemodialysis * Patient has another participant biomedical research on a drug to prevent drug interactions * Patient minor * Patient major protected (protection of the court, wardship, trusteeship) * Patient admitted for emergency or incapable of consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Osteoarticular infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Amiens
Amiens, Picardie, 80054, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.